FluroTech: Know Your Product, Improve Your Profits
July 9th, 2019
App, Exclusive, News, Top Story
Regulations surrounding the legal sale of cannabis can be byzantine, to say the least. In North America alone, 33 U.S. states have their own rules about legal use of marijuana, albeit medicinal or recreational, while the plant remains illegal at the federal level. That is unless it contains less than 0.3% tetrahydrocannabinol (THCa), in which case it qualifies as hemp and is open to interstate commerce as of the start of 2019. Canada has made marijuana legal across the country, but only in flower and oil form, while it still works to hammer out legislation allowing edibles and other cannabis-based products.
Regardless of legislation, there is a common thread across cannabis and hemp in both countries: testing. Testing is at the root of the industry as guidelines lay out strict rules for potency and safety to protect the consumer. The problem is that the testing industry is highly fragmented with varying protocols delivering inconsistent results, an issue that can frustrate the complete supply chain from cultivator to consumer, as well as those providing oversight along the way.
FluroTech Ltd. (TSX-V: TEST) (OTCQB: FLURF) is pioneering new technology addressing this nagging issue by bringing consistent testing in-house, a practice that can save resources and improve the bottom line. Using fluorescence spectroscopy and accompanying software, FluroTech’s CompleTest™ is a portable, accurate and cost effective method for cannabis and hemp testing that can shave result times down to hours rather than days or weeks. Furthermore, the technology is user friendly and doesn’t require highly trained scientists to perform the tests and analyze the results.
THC and CBD First
FluroTech co-founder and CEO Danny Dalla-Longa recently told CFN Media’s Laura Albers in an interview at MJ Micro Conference that the company has begun marketing its award-winning CompleTest™ for THC and cannabidiol (CBDa) with plans to “shortly” be expanding into testing of hemp.
THC and CBD are the two best-known components, called cannabinoids, of cannabis. THC is responsible for the “high” synonymous with ingesting marijuana, while CBD has been widely hailed for a bevy of therapeutic benefits ranging from reducing anxiety to treating difficult diseases like epilepsy and cancer.
Despite these two cannabinoids being at the core of the market, getting repeatable, reliable and accurate test results has been an industry challenge, even with today’s machines costing up to $500,000.
Consider a study conducted by Washington Cannabis Farmers Council analyzing THC content in a cannabis strain across eight different labs.
The highest reported level (26.90%) was more than twice that of the lowest level (13.37%).
Obviously, the implications regarding potency are clear enough from a consumer standpoint. But, what about the cultivator? In Canada, many licensed producers model a 1% increase in potency leading to an additional 80 cents per gram in selling price. Using an average of, say, $10 per gram, that’s an 8% increase in margin.
On that note, a recent study showed that growers using CompleTest™ were able to identify lighting solutions that increased potency by 50 percent. This was attainable owing to the ease of use to perform repeated tests and monitor the plant’s qualities.
The savings and profits resonate with respect to ROI for the $18,000 investment for the CompleTest™ system unit (plus any costs for additional scopes and test kits). This goes without putting a figure on the price of confidence in product and potential expenses related to any undiscovered contaminants or inaccurate product labeling that can earn the ire of regulators and customers.
In a Class By Itself
Dalla-Longa is another example of a successful businessman (a partner at a large accounting firm in fact) that ventured into the cannabis space because of the opportunity. He teamed up with FluroTech CTO Dr. Elmar Prenner, a specialist in fluorescence spectroscopy and the brains behind the CompleTest™ technology, to address unmet needs in testing, which he identifies as accuracy, cost, timeliness and format.
“No one is really a competitor to us now because we’re going to be offering a service to cannabis and hemp companies where they can do their own in-house testing such that as the plant is growing they will be able to test it, determine which inputs will give them the highest value for their crops,” said Dalla-Longa in the interview. He continued, “Then when they have to go to the certified labs, or the outside verification, they will know what they’ve got when they get there.”
Biomarker, People Testing and More
Without accounting for sales that are getting underway, Dalla-Longa says that the company has enough cash on hand to operate for about one year. However, part of the reason for presenting at the MJ Micro show was to speak with potential joint venture partners and align to raise capital for upcoming developments that will continue to differentiate the company from any potential future competition.
On the immediate agenda for FluroTech is finishing development of the cannabis testing technology for detecting pesticides, chemicals, mold and heavy metals, which is almost complete. The company also is working on cutting-edge biomarker technology where nanoparticles will be absorbed through a plant’s root system and carried throughout the entire cannabis or hemp plant, effectively implanting a specific biological marker that will uniquely identify that plant throughout its entire life cycle.
Finally, FluroTech is working on what it simply calls “people testing.” This is addressing different market segments for testing to identify consumer usage in environments such as roadside stops and work settings.
A Big Niche
Some may consider testing a niche as part of the massive cannabis market. Fair enough, but it is a very big niche already projected at $2.75 billion that is part and parcel to the business. FluroTech Ltd. (TSX-V: TEST) (OTCQB: FLURF) is in the catbird’s seat on this front with a first mover advantage and technology that is faster, more reliable/repeatable, accurate, and cost effective than traditional laboratory testing.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.